<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05097365</url>
  </required_header>
  <id_info>
    <org_study_id>SLE and DNA methylation</org_study_id>
    <nct_id>NCT05097365</nct_id>
  </id_info>
  <brief_title>Methyl-donor Nutrient Supplementation and Methylation Profile in Lupus Patients With Obesity</brief_title>
  <official_title>Effect of Methyl-donor Nutrient Supplementation on Methylation Profile of Inflammatory-related Genes in Lupus Patients With Obesity: a Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sao Paulo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Sao Paulo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dietary supplementation with methyl donors has been demonstrated to increase DNA methylation&#xD;
      in leucocytes whereas a limited dietary intake of methyl donors was associated with DNA&#xD;
      hypomethylation. Considering SLE disease, previously study showed that high doses of vitamin&#xD;
      B6 and folate were associated with less severe SLE. Furthermore, some evidences reported a&#xD;
      relatively high incidence of decreased serum B12 levels in rheumatic patients. This led to&#xD;
      the suggestion that diets rich in methyl group donors could have beneficial effects on SLE.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">December 31, 2026</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline on DNA methylation profile at 12 weeks</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Percentage of DNA methylation level</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline on weight at 12 weeks</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Weight in kilograms</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline on serum vitamin B12 concentrations at 12 weeks</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Serum vitamin B12 concentrations in pg/mL</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline on serum folic acid concentrations at 12 weeks</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Serum folic acid concentrations in ng/mL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Age of onset</measure>
    <time_frame>Baseline</time_frame>
    <description>Units of Measure: years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of disease since diagnosis</measure>
    <time_frame>Baseline</time_frame>
    <description>Units of Measure: years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on miR-146 expression at 12 weeks</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Relative miR-146 expression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on miR-181 expression at 12 weeks</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Relative miR-181 expression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on miR-21 expression at 12 weeks</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Relative miR-21 expression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on miR-126 expression at 12 weeks</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Relative miR-126 expression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on DNMT3 gene expression at 12 weeks</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Relative gene expression of DNMT3</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on DNMT1 gene expression at 12 weeks</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Relative gene expression of DNMT1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on global DNA hydroxymethylation at 12 weeks</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Percentage of global DNA hydroxymethylation level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on serum leptin concentrations at 12 weeks</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Serum leptin concentration in ng/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on serum C-reactive protein concentrations at 12 weeks</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Serum C-reactive protein concentration in ng/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on serum adipokines concentrations at 12 weeks</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Serum adipokines concentration in ng/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on serum triglycerides concentrations at 12 weeks</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Serum triglycerides concentration in mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on serum cholesterol concentrations at 12 weeks</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Serum cholesterol concentrations in mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on serum glucose concentrations at 12 weeks</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Serum glucose concentrations in mg/dL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on dietary intake at 12 weeks</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on abdominal circumference at 12 weeks</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Abdominal circumference in centimeters</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on fat mass at 12 weeks</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Fat mass in kilograms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on body mass index at 12 weeks</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Body mass index in kilograms/meters^2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline on height at 12 weeks</measure>
    <time_frame>Baseline and 12 weeks</time_frame>
    <description>Height in meters</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">48</enrollment>
  <condition>Obesity</condition>
  <condition>Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>Supplemented Lean Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Supplemented Obese Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Lean Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Obese Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin B12 + folic acid supplementation</intervention_name>
    <description>A 12 weeks parallel-group randomised controlled trial will be performed, in which erythematous lupus patients will complete a vitamin B12 and folic acid supplementation, in addition to the usual therapy. The dietary supplementation will be by capsules, which will content 400 mcg of folic acid and 2000 mcg of vitamin B12 each.</description>
    <arm_group_label>Supplemented Lean Group</arm_group_label>
    <arm_group_label>Supplemented Obese Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo supplementation</intervention_name>
    <description>A 12 weeks parallel-group randomised controlled trial will be performed, in which erythematous lupus patients will complete a placebo supplementation.The placebo and vitamin B12 + folic acid supplement will be indistinguishable in terms of taste, smell, and appearance.</description>
    <arm_group_label>Control Lean Group</arm_group_label>
    <arm_group_label>Control Obese Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        - Female&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  In pre-menopausal period&#xD;
&#xD;
          -  Aged between 18 to 40 years&#xD;
&#xD;
          -  Patients that meet the classification criteria according to Systemic Lupus&#xD;
             International Collaborating Clinics classification criteria (SLICC)&#xD;
&#xD;
          -  Patients with SLEDAI score ≤ 4 on Systemic Lupus Erythematosus Disease Activity Index&#xD;
             2000 (SLEDAI-2K)&#xD;
&#xD;
          -  Under glucocorticoid treatment at a dosage &lt;10 mg/day&#xD;
&#xD;
          -  Under treatment with chloroquine at a stable dose&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Infection&#xD;
&#xD;
          -  Diabetes&#xD;
&#xD;
          -  Smokers&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Univsersity of Sao Paulo</name>
      <address>
        <city>Sao Paulo</city>
        <zip>05508-030</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 10, 2021</study_first_submitted>
  <study_first_submitted_qc>October 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2021</study_first_posted>
  <last_update_submitted>October 15, 2021</last_update_submitted>
  <last_update_submitted_qc>October 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sao Paulo</investigator_affiliation>
    <investigator_full_name>Bruno Gualano</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Folic Acid</mesh_term>
    <mesh_term>Vitamin B 12</mesh_term>
    <mesh_term>Hydroxocobalamin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

